<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04697303</url>
  </required_header>
  <id_info>
    <org_study_id>STARS-RC01</org_study_id>
    <nct_id>NCT04697303</nct_id>
  </id_info>
  <brief_title>Cross-sectional Study of Anorectal Function and Quality of Life in Patients With Middle and Low Rectal Cancer</brief_title>
  <official_title>Cross-sectional Study of Anorectal Function and Quality of Life in Patients With Middle and Low Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Quan Wang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Hospital of Jilin University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Understanding the quality of life and anorectal function changes in patients with middle and&#xD;
      low rectal cancer after surgery can guide patients to recover after surgery and provide a&#xD;
      valuable reference for surgeons in the selection of surgical methods. The purpose of this&#xD;
      study is to: (1) Investigate the complication rate, recurrence and metastasis rate and&#xD;
      survival of patients with middle and low rectal cancer. (2) QLQ-C30 and QLQ-CR29&#xD;
      questionnaires were used to assess the quality of life of patients with low- and middle-level&#xD;
      rectal cancer at different periods after surgery. (3) Wexner constipation score and LARS&#xD;
      syndrome score for anorectal function after operation for low rectal cancer. (4) The CIPE&#xD;
      ejaculatory function score, IIEF-5 International Erectile Function Score, and FSFI-6 Female&#xD;
      Sexual Function Index were used to assess the changes in sexual function of patients with&#xD;
      low- and middle-position rectal cancer after surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 26, 2020</start_date>
  <completion_date type="Actual">March 28, 2021</completion_date>
  <primary_completion_date type="Actual">February 28, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>five years after the operation</time_frame>
    <description>defined as time from the date of sugery to death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>QLQ-C30</measure>
    <time_frame>Every three months after the operation</time_frame>
    <description>the score of Quality of life questionnaire QLQ-C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QLQ-CR29</measure>
    <time_frame>Every three months after the operation</time_frame>
    <description>the score of Quality of life questionnaire QLQ-C29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wexner</measure>
    <time_frame>Every three months after the operation</time_frame>
    <description>the score of questionnaire Wexner</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LARS</measure>
    <time_frame>Every three months after the operation</time_frame>
    <description>the score of questionnaire LARS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IIEF-5</measure>
    <time_frame>Every three months after the operation</time_frame>
    <description>the score of questionnaire IIEF-5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CIPE</measure>
    <time_frame>Every three months after the operation</time_frame>
    <description>the score of questionnaire CIPE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FSFI-6</measure>
    <time_frame>Every three months after the operation</time_frame>
    <description>the score of questionnaire FSFI-6</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">600</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Middle and low rectal cancer</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>anorectal function test</intervention_name>
    <description>anorectal function test</description>
    <arm_group_label>Middle and low rectal cancer</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Postoperative patients with middle and low rectal cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Postoperative patients with middle rectal cancer&#xD;
&#xD;
          2. Postoperative patients with low rectal cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        (1)Patients refused to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Jilin University First Hospital</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 1, 2021</study_first_submitted>
  <study_first_submitted_qc>January 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2021</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The First Hospital of Jilin University</investigator_affiliation>
    <investigator_full_name>Quan Wang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

